RLMD
NASDAQ · Pharmaceuticals
Relmada Therapeutics Inc
$4.23
+0.07 (+1.68%)
Open$4.16
Previous Close$4.16
Day High$4.25
Day Low$4.15
52W High$8.00
52W Low$1.47
Volume—
Avg Volume1.51M
Market Cap448.01M
P/E Ratio—
EPS$-0.96
SectorPharmaceuticals
Analyst Ratings
Strong Buy
11 analysts
Price Target
+783.5% upside
Current
$4.23
$4.23
Target
$37.37
$37.37
$22.23
$37.37 avg
$43.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 81.98M | 84.82M | 68.85M |
| Net Income | 12.35M | 12.13M | 11.14M |
| Profit Margin | 15.1% | 14.3% | 16.2% |
| EBITDA | 16.29M | 17.92M | 12.74M |
| Free Cash Flow | 15.25M | 10.32M | 8.64M |
| Rev Growth | +24.2% | +0.2% | +22.0% |
| Debt/Equity | 0.79 | 0.99 | 1.00 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,170.14 | +0.45% | 40.7 | 1.09T |
| JNJ | Johnson & Johnson | $269.19 | -0.10% | 30.6 | 644.12B |
| MRK | Merck & Co. Inc. | $150.91 | +0.94% | 114.0 | 361.66B |
| PFE | Pfizer Inc. | $27.93 | +0.68% | 36.4 | 157.54B |
| BMY | Bristol-Myers Squibb Co | $62.25 | -0.59% | 13.9 | 128.81B |
| ZTS | Zoetis Inc | $72.86 | +2.15% | 11.5 | 30.15B |